August 1, 2025Cancer MedicineOpen Access

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational study shows 70% best overall response in relapsed/refractory DLBCL using Pola-ZR or Pola-ZG, indicating effective new therapy.

The best overall response rate was 70%, with 77.77% for Pola-ZR and 63.6% for Pola-ZG.
Median progression-free survival was 8.3 months, higher than traditional salvage therapies' outcomes.
A prospective observational study followed 22 patients over 16.1 months to assess effectiveness and safety.
Findings suggest Pola-ZR/G provides clinical benefits and a tolerable safety profile for R/R DLBCL patients.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational study shows 70% best overall response in relapsed/refractory DLBCL using Pola-ZR or Pola-ZG, indicating effective new therapy.